RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Realbio Technology (RBT), a Shanghai genomic screening company, raised $15 million in a Series A+ funding. The company has a dual focus on colorectal and microbiome screening. RBT operates in three areas: REALGENE provides scientific research services; REALMED offers early detection of disease based on genomic sequencing including microbiome research, and REALAGR specializes in animal genomics. Founded in 2014, RBT has set up branches in Hangzhou, Qindao, Guiyang and other places.
Source: China Biotoday
